Correlation Between Caribou Biosciences and BriaCell Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Caribou Biosciences and BriaCell Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Caribou Biosciences and BriaCell Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Caribou Biosciences and BriaCell Therapeutics Corp, you can compare the effects of market volatilities on Caribou Biosciences and BriaCell Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Caribou Biosciences with a short position of BriaCell Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Caribou Biosciences and BriaCell Therapeutics.

Diversification Opportunities for Caribou Biosciences and BriaCell Therapeutics

-0.01
  Correlation Coefficient

Good diversification

The 3 months correlation between Caribou and BriaCell is -0.01. Overlapping area represents the amount of risk that can be diversified away by holding Caribou Biosciences and BriaCell Therapeutics Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BriaCell Therapeutics and Caribou Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Caribou Biosciences are associated (or correlated) with BriaCell Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BriaCell Therapeutics has no effect on the direction of Caribou Biosciences i.e., Caribou Biosciences and BriaCell Therapeutics go up and down completely randomly.

Pair Corralation between Caribou Biosciences and BriaCell Therapeutics

Given the investment horizon of 90 days Caribou Biosciences is expected to under-perform the BriaCell Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Caribou Biosciences is 2.48 times less risky than BriaCell Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The BriaCell Therapeutics Corp is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  30.00  in BriaCell Therapeutics Corp on September 26, 2024 and sell it today you would lose (6.00) from holding BriaCell Therapeutics Corp or give up 20.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy98.41%
ValuesDaily Returns

Caribou Biosciences  vs.  BriaCell Therapeutics Corp

 Performance 
       Timeline  
Caribou Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Caribou Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Caribou Biosciences is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.
BriaCell Therapeutics 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in BriaCell Therapeutics Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, BriaCell Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Caribou Biosciences and BriaCell Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Caribou Biosciences and BriaCell Therapeutics

The main advantage of trading using opposite Caribou Biosciences and BriaCell Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Caribou Biosciences position performs unexpectedly, BriaCell Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BriaCell Therapeutics will offset losses from the drop in BriaCell Therapeutics' long position.
The idea behind Caribou Biosciences and BriaCell Therapeutics Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Transaction History
View history of all your transactions and understand their impact on performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios